Platforms for Personalized Polytherapeutics Discovery in COVID-19

The COVID-19 pandemic entered its third and most intense to date wave of infections in November 2020. This perspective article describes how combination therapies (polytherapeutics) are a needed focus for helping battle the severity of complications from SARS-CoV-2 infection. It outlines the types o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, Christopher, Onweni, Chidinma, Zambito, Victoria, Fairweather, DeLisa, McCormick, Kathryn, Ebihara, Hideki, Caulfield, Thomas, Zhang, Yu Shrike, Freeman, W. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979270/
https://www.ncbi.nlm.nih.gov/pubmed/33753053
http://dx.doi.org/10.1016/j.jmb.2021.166945
Descripción
Sumario:The COVID-19 pandemic entered its third and most intense to date wave of infections in November 2020. This perspective article describes how combination therapies (polytherapeutics) are a needed focus for helping battle the severity of complications from SARS-CoV-2 infection. It outlines the types of systems that are needed for fast and efficient combinatorial assessment of therapeutic candidates. Proposed are micro-physiological systems using human iPSC as a format for tissue-specific modeling of infection, the use of gene-humanized zebrafish and C. elegans for combinatorial drug screens due to the animals being addressable in liquid multi-well formats, and the use of engineered pseudo-typing systems to safely model infection in the transgenic animals and engineered tissue systems.

Ejemplares similares